PReS13-SPK-1292: Gut microbiome and metabolism

Por Tilg, H
Publicado em 2013

Diet and relapsing ulcerative colitis: take off the meat?

Por Tilg, H, Kaser, A
Publicado em 2004

Predicting mortality by the Glasgow alcoholic hepatitis score: the long awaited progress?

Por Tilg, H, Kaser, A
Publicado em 2005

Interferon-alpha (IFN-α) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway

Por Kaser, A, Enrich, B, Ludwiczek, O, Vogel, W, Tilg, H
Publicado em 1999

Cachexia and tumour necrosis factor-alpha in cytomegalovirus infection.

Por Tilg, H, Vogel, W, Herold, M, Aulitzky, W E, Huber, C
Publicado em 1991

Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease

Por LUDWICZEK, O, VANNIER, E, BORGGRAEFE, I, KASER, A, SIEGMUND, B, DINARELLO, C A, TILG, H
Publicado em 2004

Serum neopterin concentrations in chronic liver disease.

Por Wilmer, A, Nölchen, B, Tilg, H, Herold, M, Pechlaner, C, Judmaier, G, Dietze, O, Vogel, W
Publicado em 1995

Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma).

Por Aulitzky, W E, Grosse-Wilde, H, Westhoff, U, Tilg, H, Aulitzky, W, Gastl, G, Herold, M, Huber, C
Publicado em 1991

The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss

Por Moschen, A R, Kaser, A, Enrich, B, Ludwiczek, O, Gabriel, M, Obrist, P, Wolf, A M, Tilg, H
Publicado em 2005

Adiponectin and its receptors in non-alcoholic steatohepatitis

Por Kaser, S, Moschen, A, Cayon, A, Kaser, A, Crespo, J, Pons-Romero, F, Ebenbichler, C F, Patsch, J R, Tilg, H
Publicado em 2005

Interferon-α induces interleukin-18 binding protein in chronic hepatitis C patients

Por KASER, A, NOVICK, D, RUBINSTEIN, M, SIEGMUND, B, ENRICH, B, KOCH, R O, VOGEL, W, KIM, S H, DINARELLO, C A, TILG, H
Publicado em 2002

In-vitro and in-vivo studies on the induction of neopterin biosynthesis by cytokines, alloantigens and lipopolysaccharides (LPS)

Por Troppmair, J., Nachbaur, K., Herold, M., Aulitzky, W., Tilg, H., Gastl, G., Bieling, P., Kotlan, B., Flener, R., Mull, B., Aulitzky, W. O., Rokos, H., Huber, Ch.
Publicado em 1988

A randomised placebo controlled trial of pegylated interferon α in active ulcerative colitis

Por Tilg, H, Vogelsang, H, Ludwiczek, O, Lochs, H, Kaser, A, Colombel, J-F, Ulmer, H, Rutgeerts, P, Krüger, S, Cortot, A, D’Haens, G, Harrer, M, Gasche, C, Wrba, F, Kuhn, I, Reinisch, W
Publicado em 2003

European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis

Por Stange, E F, Travis, S P L, Vermeire, S, Beglinger, C, Kupcinskas, L, Geboes, K, Barakauskiene, A, Villanacci, V, Von Herbay, A, Warren, B F, Gasche, C, Tilg, H, Schreiber, Stefan W, Schölmerich, J, Reinisch, W
Publicado em 2006

Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ

Por Tilg, H, van Montfrans, C, van den Ende, A, Kaser, A, van Deventer, S J H, Schreiber, S, Gregor, M, Ludwiczek, O, Rutgeerts, P, Gasche, C, Koningsberger, J C, Abreu, L, Kuhn, I, Cohard, M, LeBeaut, A, Grint, P, Weiss, G
Publicado em 2002